Higher Risk of Proteinuria with Atezolizumab plus Bevacizumab than Lenvatinib in First-Line Systemic Treatment for Hepatocellular Carcinoma

Higher Risk of Proteinuria with Atezolizumab plus Bevacizumab than Lenvatinib in First-Line Systemic Treatment for Hepatocellular Carcinoma

Introduction: Proteinuria presents a challenging complication during systemic therapy for hepatocellular carcinoma (HCC). This study aims to identify risk factors for proteinuria in patients with HCC treated with atezolizumab plus bevacizumab (Atezo/Bev) or lenvatinib (LEN) as first-line systemic tr...

Full description

Bibliographic Details
Main Authors: Jiwon Yang, Won-Mook Choi, Hyung-Don Kim, Jonggi Choi, Changhoon Yoo, Danbi Lee, Ju Hyun Shim, Kang Mo Kim, Young-Suk Lim, Han Chu Lee
Format: Article
Language:English
Published: Karger Publishers 2024-10-01
Series:Liver Cancer
Subjects:
liver cancer
adverse events
risk factor
systemic treatment
vascular endothelial growth factor
Online Access:https://beta.karger.com/Article/FullText/541621

Internet

https://beta.karger.com/Article/FullText/541621

Similar Items